Novo Nordisk licenses oral GLP-1/GIP dual agonist HRS-1596 from Hengrui for $300M upfront, with potential $2.6B in milestone payments.

Keros Therapeutics enrolls first patient in Phase 2 rinvatercept DMD trial to evaluate myostatin/activin inhibition for Duchenne muscular dystrophy.

CIRM awards Fate Therapeutics $15M to advance FT819 lupus nephritis trial, testing allogeneic CAR T-cell therapy in patients failing...

4D-150 Gene Therapy enters Phase 3 testing for diabetic macular edema, aiming to replace recurring anti-VEGF injections with a...

FDA approves DEGEVMA biosimilar to Xgeva for cancer bone complications, expanding the competitive denosumab market following Sandoz's earlier approval.

A mid-trial primary outcome amendment in a thrombectomy study reveals the operational chain reaction sites and sponsor clinops teams...

Romiesa Hagoug, Head of Project Management at Image Analysis Group (IAG), on what a site's first scan reveals, how...

WILLOW Cohort B's p=0.14 masked a 58% BICLA response at the lowest dose. The drug worked. The endpoint couldn't...

Inventiva's lanifibranor faces cash runway pressure as it awaits Phase 3 MASH data readout. Enrollment pace will determine financing...

Innovent and Takeda expand the Phase 3 MarsLight-11 Trial to include non-squamous NSCLC patients, doubling the addressable population for...